HKAM
PGNX

Horizon Kinetics Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Horizon Kinetics Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-67,200
Closed -$340K – 490
2019
Q3 		$340K Hold
67,200
– – 0.01% 296
2019
Q2 		$415K Hold
67,200
– – 0.01% 279
2019
Q1 		$312K Buy
+67,200
New +$304K 0.01% 409

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Horizon Kinetics Asset Management's PGNX Position: Q4 2019 in Review

Horizon Kinetics Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 67,200 shares — an estimated $340K sold.

Horizon Kinetics Asset Management first reported a position in PGNX in Q1 2019 and held it in 3 quarters. The position peaked at $415K in Q2 2019. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • Horizon Kinetics Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Horizon Kinetics Asset Management sold 67,200 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $340K.
  • Horizon Kinetics Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2019 and held it in 3 quarters.
  • Horizon Kinetics Asset Management's Progenics Pharmaceuticals Inc position peaked at $415K in Q2 2019.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Horizon Kinetics Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.